Omnicell Inc. (OMCL) Releases Q3 Earnings Guidance

Posted by on Jul 31st, 2016

Omnicell Inc. (NASDAQ:OMCL) issued an update on its third quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.38-0.42 for the period, compared to the Thomson Reuters consensus estimate of $0.40. The company issued revenue guidance of $176-183 million, compared to the consensus revenue estimate of $178.36 million.Omnicell also updated its FY16 guidance to $1.50-1.60 EPS.

Shares of Omnicell Inc. (NASDAQ:OMCL) remained flat at $36.22 during trading on Thursday. The stock had a trading volume of 120,164 shares. Omnicell Inc. has a 12-month low of $25.06 and a 12-month high of $40.01. The company has a market capitalization of $1.30 billion and a P/E ratio of 54.47. The firm’s 50-day moving average price is $34.70 and its 200 day moving average price is $30.25.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 28th. The company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. The business earned $175.60 million during the quarter, compared to the consensus estimate of $170.89 million. The firm’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 EPS. On average, equities analysts anticipate that Omnicell Inc. will post $1.56 EPS for the current fiscal year.

Several analysts recently commented on OMCL shares. FBR & Co lifted their price objective on Omnicell from $35.00 to $40.00 and gave the stock an outperform rating in a report on Thursday, July 7th. Zacks Investment Research raised Omnicell from a sell rating to a hold rating in a report on Wednesday, June 29th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $37.25.

In other news, Director Sara J. White sold 2,000 shares of the business’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $31.76, for a total value of $63,520.00. Following the transaction, the director now directly owns 40,433 shares in the company, valued at $1,284,152.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Robin Gene Seim sold 6,407 shares of the business’s stock in a transaction dated Friday, April 29th. The stock was sold at an average price of $31.00, for a total value of $198,617.00. Following the completion of the sale, the executive vice president now owns 59,619 shares in the company, valued at $1,848,189. The disclosure for this sale can be found here.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.